CCM
NRIX icon

Cinctive Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Cinctive Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-45,171
Closed -$700K – 515
2026
Q1 		$700K Sell
45,171
-2,536
-5% -$42K 0.05% 275
2025
Q4 		$905K Sell
47,707
-143,308
-75% -$2.06M 0.05% 290
2025
Q3 		$1.76M Buy
191,015
+74,882
+64% +$778K 0.08% 265
2025
Q2 		$1.32M Buy
116,133
+77,363
+200% +$836K 0.07% 257
2025
Q1 		$461K Sell
38,770
-120,202
-76% -$2.01M 0.04% 266
2024
Q4 		$3M Buy
158,972
+53,744
+51% +$1.23M 0.15% 187
2024
Q3 		$2.36M Buy
+105,228
New +$2.38M 0.13% 218

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cinctive Capital Management's NRIX Position: Q2 2026 in Review

Cinctive Capital Management sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 45,171 shares — an estimated $700K sold.

Cinctive Capital Management first reported a position in NRIX in Q3 2024 and held it in 7 quarters. The position peaked at $3M in Q4 2024. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Cinctive Capital Management reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Cinctive Capital Management sold 45,171 Nurix Therapeutics shares in Q2 2026, an estimated $700K.
  • Cinctive Capital Management first reported a position in Nurix Therapeutics in Q3 2024 and held it in 7 quarters.
  • Cinctive Capital Management's Nurix Therapeutics position peaked at $3M in Q4 2024.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.